BEIJING, China – Paul Grayson scoffs at the biopharma executives who trumpet their expensive search for new biologic targets to create completely novel, and crazily expensive biologics. He said that approach does not apply to cost-sensitive China and he is championing a new definition of "novel" biologics in his development of an antibody for rheumatoid arthritis and other products.